|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Expert Opin Pharmacother. 2012 Feb;13(2):245-54.
Source: http://www.ncbi.nlm.nih.gov/pubmed/22242973
Adefovir dipivoxil in chronic hepatitis B: history and current uses.
Segovia MC, Chacra W, Gordon SC.
SourceDivision of Gastroenterology and Hepatology, Henry Ford Health System
, 2799 West Grand Boulevard, Detroit, MI 48202 , USA +1 313 916 9465 ; +1
313 916 9487 ; [email protected]. Abstract Introduction: The nucleotide
analogue adefovir dipivoxil (ADV) was approved in 2002 for the treatment of
chronic infection with hepatitis B virus (HBV), in both hepatitis B e
antigen (HBeAg)-positive and -negative patients. ADV 10 mg daily has been
associated with improved liver histology, decreased levels of HBV DNA and
alanine aminotransferase (ALT), and seroconversion of HBeAg. Areas covered:
This paper reviews the use of ADV as a first-line treatment for chronic
hepatitis B and as an add-on therapy in chronic HBV-infected patients with
lamivudine resistance. In the years since its launch, clinical resistance
to ADV has emerged, and tenofovir and entecavir have shown greater efficacy
in reducing viral load. Expert opinion: Many patients who started
antiviral therapy with ADV (either as monotherapy or in combination with
lamivudine) remain on this agent because they have undetectable viremia,
but its future use will probably diminish because of the availability of
more potent drugs. ADV is generally well tolerated, though the 10 mg dose
is associated with low risk of nephrotoxicity.
|
|
发表于 2012-1-24 09:21